Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 1Lymphoid 1

Conditions

Mycosis Fungoides 3Recurrence 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Natural Killer/T-cell Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Glioma 1Glioblastoma 1Carcinoma in Situ 1

Interventions

Temozolomide 4Specimen Handling 3Magnetic Resonance Spectroscopy 3Paclitaxel 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cognitive Behavioral Therapy 2Blood Specimen Collection 2Azacitidine 2vocimagene amiretrorepvec 1trametinib 1sonidegib 1sargramostim 1ruxolitinib 1rucaparib 1ribociclib 1repotrectinib 1imetelstat 1fludarabine 1epacadostat 1dostarlimab 1depatuxizumab 1ceritinib 1cemiplimab 1cc-486 1carboxyamido-triazole 1acalabrutinib 1abiraterone 1Uncertainty 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × cemiplimab × Lymphoid × Clear all
NCT04826393 2025-10-22

ASP8374 + Cemiplimab in Recurrent Glioma

Dana-Farber Cancer Institute

Phase 1 Completed
14 enrolled
CNSLymphoid

Glioblastoma, Glioma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡